Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1.125 1.10 1.15 1.125 1.10 1.125 755,437 08:09:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.4 -1.4 -0.2 - 12

Feedback PLC Half-year Report

23/02/2021 7:00am

UK Regulatory (RNS & others)


Feedback (LSE:FDBK)
Historical Stock Chart


From Feb 2021 to Mar 2021

Click Here for more Feedback Charts.

TIDMFDBK

RNS Number : 9572P

Feedback PLC

23 February 2021

This announcement contains inside information as stipulated under the UK Market Abuse Regulations (MAR).

Feedback plc

Interim Results for the six months to 30 November 2020

Significant momentum in creating scalable platform for Bleepa

London, UK, 23 February 2021 - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces its unaudited results for the six months to 30 November 2020.

The focus during the period was on advancing Bleepa's proposition by creating strong platforms for growth both via product enhancement and collaborations as well as receiving industry recognition within key markets and frameworks.

Operational highlights (including post period-end)

-- As at 30 November 2020, 359 Bleepa users across 10 specialties at Royal Oldham Hospital, an increase of 274 users since completion of the pilot

   --      Wider range of potential revenue streams through broadening market scope 
   --      Significant progression in developing Bleepa's offering, scalability and security: 

o Attainment of CE mark, confirming use of Bleepa as a Class 1 Medical Device

o Appointment to NHSx Framework

o Addition of 3D Imaging offering with Axial3D Partnership

o Selection for WISH 2020 innovation awards, Digitalhealth.London 2020 Programme & DIT's virtual event to India

o Significant barriers to entry overcome through certification of Cyber Essentials Plus and passing of ISO 27001 ISMS standard

   --      Strengthening of the Board through appointment of Philipp Prince as Non-executive director 

-- Recruitment of marketing specialists both in the UK and India to expediate commercial strategy

-- Raised GBP5.27m before expenses in July 2020 to further broaden the Bleepa proposition and reach

Financial summary

-- Loss after tax for the six-month period of GBP723k (H1 2019: loss GBP603k) due to development and deployment of the Company's flagship product, Bleepa including increased investment in software development of GBP672k (H1 2019: GBP301k) in line with focus on product enhancement linked to market opportunities

-- Loss before interest, tax and amortisation for the six-month period of GBP920k (H1 2019: loss GBP698k)

   --      Cash at 30 November 2020 was GBP3.78m (30 November 2019: GBP1.53m). 

Commenting on the results and prospects, Dr Tom Oakley, CEO of Feedback, said:

"Feedback has continued to make significant advancements in its transition into the mobile medical communications market - continuing to invest in further augmenting and expanding Bleepa's offering.

"As the restrictions imposed by the global pandemic subside, we are confident in our ability to build on the strong foundations we have now laid, and to deliver the next key milestones for the Company. Feedback is continuing commercial discussions, and while the pandemic slowed progression of Bleepa within the NHS, we are now seeing improvement in the pace of these talks, as well as a growing interest outside of the NHS and internationally.

"With Bleepa's unique flexibility, we have been able to make great strides in strengthening its proposition; through achieving the CE mark, adding new 3D imaging technology and gaining industry-standard cyber security certifications, the product now has a broadened and mature offering. Alongside its cloud-based installation scalability, Bleepa is well placed to build a strong presence in numerous markets internationally. Importantly, we have an exciting pipeline of opportunities which has grown significantly on the back of the progress made during the period. Commercialisation is clearly the key priority and we believe that we will make strong headway in this area in the coming months.

" Bleepa has the potential to fundamentally change the way in which clinicians communicate, not only making the lives of those who care for us easier day-to-day, but enabling a route to inclusive interaction within, between and spanning an entire medical provider's network to make patient information more easily accessible. We believe that Bleepa is the future of medical communications. "

Enquiries:

 
 Feedback plc                                        +44 (0) 20 3997 7634 
  Tom Oakley, CEO                                     IR@fbk.com 
  Lindsay Melvin, CFO 
 
 Allenby Capital Limited (Nominated Adviser) 
  David Worlidge / Asha Chotai                       +44 (0)20 3328 5656 
 
 Peterhouse Corporate Finance Ltd (Joint Broker) 
  Lucy Williams / Duncan Vasey                       +44 (0)20 7469 0936 
 
 Stanford Capital Partners Limited (Joint Broker) 
  Patrick Claridge / John Howes                      +44 20 3815 8880 
 
 Walbrook PR Ltd                                     Tel: 020 7933 8780 or 
                                                      feedbackplc@walbrookpr.com 
 Paul McManus/Nick Rome/Nicholas Johnson             07980 541 893 or 07748 
                                                      325 236 or 07884 664 
                                                      686 
 

Notes to editors

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

Chairman and Chief Executive's Statement

Feedback has made strong progress during the period. The standout achievement was receipt of the CE mark - confirming use of Bleepa as a Class 1 Medical Device. This was key in providing further confidence in the imaging app and setting it apart from unregulated competitors whilst creating a strong barrier to entry. In addition to this, we further developed the technology platform, its security offering and routes to market and are encouraged by the response received to date.

The focus during the period was very much on establishing a platform for growth and increasing our marketing and development opportunities. To that end, we were delighted to raise GBP5.27m (before expenses) via a placing and open offer in July 2020, enabling the Company to focus investment on sales, product development and geographic expansion. Importantly, we strengthened our marketing team and hired an integration specialist in order to help increase the speed of roll out. Furthermore, investment into our infrastructure and operating platform has laid the foundations for product enhancements, making Bleepa more attractive to a wider audience.

Product enhancement focused on three areas; scalability - through the creation of a cloud infrastructure that will enable Bleepa to be deployed more cost effectively and ensure that performance is maintained during peak usage; security - through integration with hospital user administration systems that enable customers to manage user accounts (also reducing our administrative costs); and the addition of new key features following customer feedback and market opportunities.

These included improvements to the image viewer to enhance the user experience, further differentiating Bleepa from competitors and enhancing the CE marked features. Additionally, the development of photocapture enables clinical users to use Bleepa to acquire clinical photos of wounds and lesions in a unique zero footprint method. We also added document management functionality to enable Bleepa to store and present non imaging patient information such as laboratory reports. The photocapture module opens up wider clinical opportunities in the fields of dermatology and community wound management, with document management enhancing the value proposition of Bleepa in the multidisciplinary team (MDT) setting.

The NHS remains a key cornerstone of our growth market - with ongoing trials at The Royal Oldham Hospital, part of the Pennine Acute Hospitals NHS Trust based around Manchester, and the Royal Papworth Hospital NHS Foundation Trust in Cambridge continuing to progress following positive feedback and renewals. Active discussions continue with Pennine and a number of other NHS sites.

While COVID has been an unpredictable force in this last year, it has clearly shown the need for Bleepa within the clinical setting - with the app being actively used as a tool within the COVID response at The Royal Oldham Hospital. As at 30 November 2020, there were 359 Bleepa users across 10 specialties at Royal Oldham Hospital, an increase of 274 users since completion of the pilot. However, while we were able to demonstrate the benefits of Bleepa, COVID has understandably consumed the bandwidth of NHS providers across the UK, extending the timescales on new engagements being finalised.

It was hoped that the NHSx Clinical Communication Tool Framework would stimulate engagement with our much-needed technology. However, at the time of writing, the directors believe that there has been no award made from the framework to any NHS Trust - testament to the fact that, even when a payment mechanism exists, Trusts have not had the bandwidth to engage due to COVID pressures. Despite these pressures we have made good headway with NHS stakeholders and have built the value proposition in partnership with our existing deployments in anticipation of being ready to address the post COVID landscape and opportunities. As providers begin to recover from the acute COVID pressures we are confident that Bleepa is now well positioned to meet their requirements and we are already seeing increased engagement from a number of Trusts.

Growth within the NHS is currently focused on individual trusts. However, we are increasingly looking at supporting wider regional service delivery and we believe that there is significant opportunity to implement solutions within a broader structure, which drove our transition from on-premise to cloud-based installation capabilities. Additionally, given the product enhancements we implemented during the period, we are now positioned to address wider clinical audiences and market opportunities.

Anticipating potential COVID delays with NHS opportunities, we took steps early in the pandemic to explore adjacent opportunities for Bleepa in different segments and have made strong groundwork in appealing to a wider customer base outside of the NHS - providing the Company with a number of new potential routes to market. These activities culminated in the Company joining a successful trade mission to India with the Department of International Trade in December 2020. This trade mission generated many promising leads that the Company is now pursuing and has led to the engagement of two contractors on the ground in India to help convert these opportunities.

Operational review

Bleepa(TM)

The Company made strong progress in developing the Bleepa proposition. Post receipt of the CE Mark, Bleepa was added to the NHSx National Clinical Communication Tool Framework ("the NCCT Framework") in July 2020. This was an important development as it provides a vehicle for NHS Trusts to buy Bleepa by drawing down from a GBP3 million centralised fund over a two-year period. It also gives Bleepa national coverage and provides an independent validation of the quality and suitability of Bleepa for frontline delivery, a stamp of approval that the Company can use to also drive sales in other markets. COVID has impacted the NHS's ability to focus outside of the immediate pandemic, but with positive ongoing discussions across multiple Trusts and potential easing of pressure on the NHS resources, we are confident in progressing these talks.

Additionally, we made further functionality enhancements by adding 3D imaging through our partnership with Axial3D. The collaboration enhances our cross-selling capabilities and is the first example of the Company's strategy to leverage its growing userbase to generate supplementary revenue, over and above the main user licence fee. We see this as an important development given our focus on broadening revenue streams from existing users and targeting a wide number of end users. We are currently working with Axial3D to identify an initial deployment site for the joint offering.

Bleepa's selections as a World Innovation Summit for Health (WISH) 2020 Innovation Booster and to participate in the Digitalhealth.London 2020 Accelerator Programme provided further welcome endorsements. Participation as an Innovation Booster at WISH 2020, an event to showcase our technology to the Middle Eastern market, provided an opportunity for the Company to exhibit Bleepa to some of the world's leading health experts, health ministers, decision-makers, and investors and we are now formulating a targeted approach into this market. Furthermore, it offers a support programme to launch into the Middle-Eastern market. Given the potential global scalability of the product, we were able to address a new potential market and to further develop the Company's international recognition.

The Digitalhealth.London 2020 Accelerator Programme aims to help 20 small and medium sized health technology companies implement its innovations into the NHS, particularly in London - and Bleepa's inclusion is recognition of the product's potential to disrupt the healthcare market and improve care delivery. There is myriad of complex care delivery challenges that occurs in London as a result of numerous teams speaking and connecting with each other, and Bleepa provides an optimised solution to these challenges. Participation in the programme will provide foundations for Bleepa to strengthen its potential reach across London. Bleepa also received High Commendation from the HTN awards for its rapid response to COVID, with our partners at Pennine Acute Hospitals NHS Trust taking the prize.

Broadening International Commercial Partnerships

Post period end, Bleepa was selected by Healthcare UK, part of the Department for International Trade ("DIT"), to join a virtual healthcare mission to India, providing further recognition of its functionality and potential market reach. India is key to our international expansion and following the successful event, we have now employed two specialists based in India to aid our entry into this large and untapped market.

We are focused on providing solutions to a range of territories, all of which have slightly different requirements and potential revenue models. The importance here is in ensuring that we are able to offer attractive solutions that can be implemented quickly and easily within existing entities.

Our ability to target a growing range of potential end users was significantly enhanced during the period as we focused on product development, and we believe that we now have the tools in place to unlock value and to become the medical communication app of choice.

Receipt of Cyber Essentials Plus and ISO 27001 certification highlights our commitment to providing clinicians with the right tools for the job and will give customers confidence about the security of data on the platform. This further reflects the importance of investment undertaken during the period - with additional security, product upgrades and new functionality paramount in helping to further cement credibility and growth opportunities.

Other Products

As previously reported, TexRAD sales have continued to decline in line with expectations, and in line with our strategy we have reduced the resourcing of this product to a minimum. Cadran continues to be employed in current contracts across a number of Trusts. Bleepa has evolved from the Cadran technology and works both with current PACs and cloud based systems. Therefore, we are confident that Bleepa offers a standalone solution for Trusts looking to advance their medical communications structures/practices.

Strengthening the Board

In July 2020, Philipp Prince joined the Company as an Independent Non-Executive Director, bringing strong capital markets and PLC experience to the Company. Given his background, he further strengthens the Board's ability to deliver a strong growth platform for Bleepa.

Financial review

In the six months to 30 November 2020, the loss after tax increased to GBP723k (H1 2019: loss GBP603k) due to a higher cost base following the recruitment programme to drive new opportunities and the development and deployment of the Company's flagship product, Bleepa. Loss before interest, tax and amortisation was GBP920k (H1 2019: loss GBP698k). During the period, Feedback invested GBP672k with Future Processing on software development of Bleepa (H1 2019: GBP301k). This intangible asset will be amortised against future income streams stemming from this investment. The tax credit reflects the research and development tax credit available to Feedback Medical.

Feedback continues to focus on rigorous cost control, with existing overheads kept well monitored. Cash at 30 November 2020 was GBP3.78m (30 November 2019: GBP1.53m) following the equity fundraise in July 2020, raising GBP5.27m before expenses.

In light of the pandemic, all staff are working remotely from home and the Company has renegotiated new rates at its physical locations to minimise spend. We have seen a further reduction in travel and associated business expenses as all customer engagements and product deployments are now fully remote. All spend is targeted at driving new business opportunities with tailored marketing to specific clinical audiences and management stakeholders as well as product development streams linked to qualified market opportunities. The Board considers the investments made to date and the current rate of spend to be necessary to position Bleepa to capitalise on the range of opportunities identified, especially in the post COVID period. All investments are kept under regular review to ensure maximum shareholder value is created.

Outlook

Feedback has continued to make significant developments in its transition to the mobile medical communications market - continuing to invest in further augmenting and expanding Bleepa's offering.

As the restrictions imposed by the global pandemic subside, we are confident in our ability to build on the strong foundations we have now laid, and to deliver the next key milestones for the Company. Feedback is continuing commercial discussions, and while the pandemic slowed progression of Bleepa within the NHS, we are now seeing improvement in the pace of these talks, as well as a growing interest outside of the NHS and internationally.

With Bleepa's considerable flexibility, we have been able to make great strides in strengthening its proposition through achieving the CE mark, adding new 3D imaging technology and gaining industry-standard cyber security certifications, the product now has a broadened and mature offering. Alongside its cloud-based installation scalability, Bleepa is well placed to build a strong presence in numerous markets internationally. Importantly, we have an exciting pipeline of opportunities which has grown significantly on the back of the progress made during the period. Commercialisation is clearly the key priority and we believe that we will make strong headway in this area in the coming months.

Dr T Oakley, CEO

Prof R Shaw, Chairman

UNAUDITED INTERIM STATEMENT OF COMPREHENSIVE INCOME

 
                                        Notes         Unaudited         Unaudited     Audited 
                                                     Six months        Six months        Year 
                                                 to 30 November    to 30 November       to 31 
                                                           2020              2019         May 
                                                        GBP'000           GBP'000        2020 
                                                                                      GBP'000 
 
 Revenue                                                    165               269         450 
 
 Cost of sales                                              (1)               (4)         (2) 
                                               ----------------  ----------------  ---------- 
 
 Gross profit                                               164               265         448 
 
 
 Other operating expenses                               (1,082)             (956)     (1,863) 
 
 
 Operating loss                                           (918)             (691)     (1,415) 
 
 Net finance income                                           -                 -           1 
                                               ----------------  ----------------  ---------- 
 
 Loss on ordinary activities before 
  taxation                                                (918)             (691)     (1,414) 
 
 Tax credit                                                 195                88         327 
                                               ----------------  ----------------  ---------- 
 
 Loss on ordinary activities 
  after tax attributable to the 
  equity shareholders of the Company                      (723)             (603)     (1,087) 
                                               ----------------  ----------------  ---------- 
 
 
 Total comprehensive loss for 
  the period                                              (723)             (603)     (1,087) 
                                               ----------------  ----------------  ---------- 
 
 
 LOSS PER SHARE (pence) 
 
 Basic and diluted                        2              (0.07)            (0.13)      (0.22) 
                                               ----------------  ----------------  ---------- 
 
 
 

UNAUDITED INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

 
                           Share      Share    Capital      Retained   Translation      Share     Total 
                         Capital    Premium    Reserve      Earnings       Reserve     Option 
                                                                                      Reserve 
                         GBP'000    GBP'000    GBP'000       GBP'000       GBP'000    GBP'000   GBP'000 
 At 1 June 2019              933      3,777        300       (4,115)         (210)        261       946 
 New Shares issued           417      1,583          -             -             -          -     2,000 
 Costs associated 
  with the raising 
  of funds                     -      (139)          -             -             -          -     (139) 
 Total comprehensive 
  expense for the 
  period                       -          -          -         (603)             -          -     (603) 
                       ---------  ---------  ---------  ------------  ------------  ---------  -------- 
 At 30 November 
  2019                     1,350      5,221        300       (4,718)         (210)        261     2,204 
 Share option 
  expense reserve              -          -                       42             -       (42)         - 
 Total comprehensive 
  expense for the 
  period                       -          -          -         (435)             -          -     (435) 
                       ---------  ---------  ---------  ------------  ------------  ---------  -------- 
 At 31 May 2020            1,350      5,221        300       (5,111)         (210)        219     1,769 
 
 New Shares issued         1,317      3,952          -             -             -                5,269 
 Costs associated 
  with the raising 
  of funds                     -      (313)          -             -             -                (313) 
 Total comprehensive 
  expense for the 
  period                       -          -          -         (723)             -                (723) 
                       ---------  ---------  ---------  ------------  ------------  ---------  -------- 
 
 At 30 November 
  2020                     2,667      8,860        300       (5,834)         (210)        219     6,002 
                       ---------  ---------  ---------  ------------  ------------  ---------  -------- 
 

UNAUDITED INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION

 
                                              Unaudited      Unaudited    Audited 
                                            30 November    30 November     31 May 
                                                   2020           2019       2020 
                                                GBP'000        GBP'000    GBP'000 
                                   Notes 
 ASSETS 
 Non-current assets 
 Property, plant and equipment                       26             11         11 
 Intangible assets                   3            1,979            753      1,297 
                                          ------------- 
                                                  2,005            764      1,309 
                                          -------------  -------------  --------- 
 Current assets 
 Trade receivables                                    -            144        100 
 Corporation tax                                    522            247        327 
 Other receivables                                   94             18         30 
 Cash and cash equivalents                        3,776          1,526        732 
                                          -------------  -------------  --------- 
                                                  4,392          1,935      1,189 
 
 Total assets                                     6,397          2,699      2,498 
                                          -------------  -------------  --------- 
 
 
 EQUITY 
 Capital and reserves 
  attributable to the Company's 
  equity shareholders 
 Called up share capital                          2,667          1,350      1,350 
 Share premium account                            8,860          5,221      5,221 
 Capital reserve                                    300            300        300 
 Translation reserve                              (210)          (210)      (210) 
  Share option expense 
   reserve                                          219            261        219 
 Retained earnings                              (5,834)        (4,718)    (5,111) 
                                          -------------  -------------  --------- 
 Total equity                                     6,002          2,204      1,769 
                                          -------------  -------------  --------- 
 
   Current liabilities 
 Trade payables                                     180            143        119 
 Other payables                                     215            346        600 
                                          ------------- 
 
                                                    395            489        719 
 
   Non-current Liabilities 
 Other payables                                       -              6         10 
                                          -------------  -------------  --------- 
 
 Total liabilities                                  395            495        729 
                                          ------------- 
 
 TOTAL EQUITY AND LIABILITIES                     6,397          2,699      2,498 
                                          -------------  -------------  --------- 
 

UNAUDITED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

 
                                                Unaudited         Unaudited      Audited 
                                               Six months        Six months         Year 
                                           to 30 November    to 30 November    to 31 May 
                                                     2020              2019         2020 
                                                  GBP'000           GBP'000      GBP'000 
 
 Cash flows from operating activities 
 Loss before tax                                    (918)             (691)      (1,414) 
                                         ----------------  ----------------  ----------- 
 Adjustments for: 
 Depreciation and amortisation                          2                 7           30 
  Share based payment expense                           -                 -           50 
 Net finance income                                     -                 -            1 
 Decrease in trade receivables                        100                58          103 
 (Increase)/Decrease in other 
  receivables                                        (64)                13           11 
 Increase in trade payables                            61               111           88 
 Increase/(Decrease) in other 
  payables                                          (395)             (143)           95 
 Corporation tax received                               -                91          249 
                                         ----------------  ----------------  ----------- 
                                                    (296)               137          627 
                                         ----------------  ----------------  ----------- 
 
 Net cash used in operating activities            (1,214)             (554)        (787) 
                                         ----------------  ----------------  ----------- 
 
 Cash flows from investing activities 
 Purchase of tangible fixed assets                   (14)              (12)          (7) 
 Purchase of intangible assets                      (684)             (310)        (876) 
 Net finance income received                            -                 -            1 
 
 Net cash used in investing activities              (698)             (322)        (882) 
                                         ----------------  ----------------  ----------- 
 
 Cash flows from financing activities 
 Net proceeds of share issue                        4,956             1,861        1,861 
                                         ----------------  ----------------  ----------- 
 
 Net cash generated from financing 
  activities                                        4,956             1,861        1,861 
                                         ----------------  ----------------  ----------- 
 
 Net increase in cash and cash 
  equivalents                                       3,044               985          192 
 Cash and cash equivalents at 
  beginning of period                                 732               541          541 
 
 Cash and cash equivalents at 
  end of period                                     3,776             1,526          733 
                                         ----------------  ----------------  ----------- 
 

NOTES TO THE UNAUDITED INTERIM REPORT

   1.             BASIS OF PREPARATION 

The accounting policies are unchanged from the financial statements for the year ended 31 May 2020.

The information set out in this interim report for the six months ended 30 November 2020 does not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006. The accounts for the year ended 31 May 2020 have been filed with the Registrar of Companies.

This interim report was approved by the directors on 22 February 2021.

   2.         LOSS PER SHARE 

Basic earnings per share are calculated by reference to the loss on ordinary activities after and on the weighted average number of shares in issue.

 
                                  Unaudited        Unaudited         Audited 
                              Six months to    Six months to         Year to 
                                30 November      30 November          31 May 
                                       2020             2019            2020 
                                    GBP'000          GBP'000         GBP'000 
 
 Net loss attributable 
  to ordinary equity 
  holders                             (723)            (603)         (1,087) 
                            ---------------  ---------------  -------------- 
 
                              Six months to    Six months to         Year to 
                                30 November      30 November          31 May 
                                       2020             2019            2020 
 Weighted average number 
  of ordinary shares 
  for basic earnings 
  per share                     971,380,047      449,131,065     498,854,027 
 Effect of dilution: 
    Share Options                         -                -               - 
       Warrants                           -                -               - 
                            ---------------  ---------------  -------------- 
 Weighted average number 
  of ordinary shares 
  adjusted for the effect 
  of dilution                   971,380,047      449,131,065     498,854,027 
                            ---------------  ---------------  -------------- 
 
 Loss per share (pence) 
    Basic                            (0.07)           (0.13)          (0.22) 
    Diluted                          (0.07)           (0.13)          (0.22) 
                            --------------- 
 
 
   3.         INTANGIBLE ASSETS 
 
                            Software         Customer   Patents   Goodwill     Total 
                                        relationships 
 
                             GBP'000          GBP'000   GBP'000    GBP'000   GBP'000 
 Cost 
 
 At 31 May 2019                1,038              100       154        272     1,564 
 Additions                       301                -         9          -       310 
                     ---------------  ---------------  --------  ---------  -------- 
 At 30 November 
  2019                         1,339              100       163        272     1,874 
 Additions                       564                -         2                  566 
                     ---------------  ---------------  --------  ---------  -------- 
 At 31 May 2020                1,903              100       165        272     2,440 
 Additions                       672                -        12          -       684 
                     ---------------  ---------------  --------  ---------  -------- 
 At 30 November 
  2020                         2,575              100       176        272     3,124 
                     ---------------  ---------------  --------  ---------  -------- 
 
 Amortisation 
 
 At 31 May 2019                  645              100        97        272     1,114 
 Charge for the 
  period                           -                -         7          -         7 
                     ---------------  ---------------  --------  ---------  -------- 
 As at 30 November 
  2019                           645              100       104        272     1,121 
 Charge for the 
  period                           -                -        22          -        22 
                     ---------------  ---------------  --------  ---------  -------- 
 At 31 May 2020                  645              100       126        272     1,143 
 Charge for the 
  period                           -                -         2          -         2 
                     ---------------  ---------------  --------  ---------  -------- 
 At 30 November 
  2020                           645              100       128        272     1,145 
                     ---------------  ---------------  --------  ---------  -------- 
 
 Net book Value 
 
 At 30 November 
  2020                         1,930                -        48          -     1,979 
                     ---------------  ---------------  --------  ---------  -------- 
 At 31 May 2020                1,258                -        39          -     1,297 
                     ---------------  ---------------  --------  ---------  -------- 
 At 30 November 
  2019                           694                -        59          -       753 
                     ---------------  ---------------  --------  ---------  -------- 
 
   4.         AVAILABILITY OF THE INTERIM REPORT 

Copies of the report will be available from the Company's registered office at Health Foundry, Canterbury House, 1 Royal Street, London SE1 7LL and also from the Company's website www.fbk.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IR PPURGPUPGGRP

(END) Dow Jones Newswires

February 23, 2021 02:00 ET (07:00 GMT)

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart
ADVFN Advertorial
Your Recent History
LSE
FDBK
Feedback
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210307 10:38:55